Post-Cardiac Arrest Syndrome - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Post-Cardiac Arrest Syndrome Emerging Therapy and TPP Insights

Thelansis's "Post-Cardiac Arrest Syndrome Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Post-Cardiac Arrest Syndrome Overview

Post-cardiac arrest syndrome is a complex response after return of circulation, involving hypoxic-ischemic brain injury, myocardial dysfunction, systemic ischemia-reperfusion inflammation, and the ongoing cause of arrest. Neurological injury may cause coma, seizures, cognitive impairment, or disability, while cardiovascular and multi-organ dysfunction can complicate recovery. Care emphasizes oxygenation, ventilation, blood-pressure support, temperature control, seizure assessment, coronary evaluation, and multimodal neuroprognostication. The 2025 AHA guideline recommends temperature control for at least 36 hours in adults who remain unresponsive after ROSC. The 2026 ICECAP trial found that longer therapeutic hypothermia did not improve neurological outcomes. With no approved drug that reliably prevents post-arrest brain injury, development is exploring mitochondrial, anti-inflammatory, metabolic, regenerative, and neuroprotective strategies. Neurological recovery remains an unmet need.

Key Highlights

• In Germany, treatable in-hospital cardiac arrest (IHCA) cases associated with Post-Cardiac Arrest Syndrome (PCAS) are projected to increase from 7,451 in 2025 to 7,640 by 2035.
• PCAS is a life-threatening condition characterized by neurological injury, myocardial dysfunction, and systemic ischemia-reperfusion injury following cardiac arrest.
• Despite advances in critical care, mortality and neurological disability remain high.
• Significant unmet need remains for therapies that improve neurological recovery and survival.

Market Overview

• The France PCAS market is projected to grow from $36M in 2025 to $65M by 2035.
• Market growth is driven by:
• Advances in targeted temperature management and critical care therapies
• Increasing research into neuroprotective and organ-protective treatments
• Future growth will depend on therapies that improve long-term neurological outcomes and survival.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Invero Pharma, Inc.